Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S1434; text: CR S1433)
This resolution designates February 27, 2025 as "Rare Disease Day" and recognizes the importance of awareness, early diagnosis, and research into rare diseases. It is a Senate simple resolution that expresses the chamber's views and makes an official designation but does not create binding law or require action by federal agencies. Such a resolution applies only to the Senate and is symbolic in nature.
This Senate resolution designates February 27, 2025, as "Rare Disease Day" and formally recognizes the importance of improving awareness, encouraging early and accurate diagnosis, and supporting national and global research on rare diseases.
The resolution cites statistics on rare disease prevalence, references the Orphan Drug Act and FDA/NIH programs, and is a non‑binding, symbolic statement of congressional recognition.
This is a nonbinding Senate resolution designating a day; it does not create binding law and thus cannot 'become law' by itself.
Relative to its intended legislative type, this bill functions as a straightforward commemorative resolution. It specifies the date to be designated and sets out concise recognition language; the factual preamble supplies context without creating legal obligations.
All support recognition, but differ on follow‑up funding and federal role
These are examples from the analysis, not a ranked list of the most-affected groups.
All support recognition, but differ on follow‑up funding and federal role
Likely strongly supportive as a humanitarian and public‑health affirmation that spotlights underserved patients and research needs.
Will welcome the recognition but note the resolution is symbolic and does not secure funding or guarantee access to treatments.
Generally favorable; sees the resolution as low‑cost, bipartisan recognition of a clear public‑health issue.
Will appreciate the non‑binding nature but will look for measurable next steps or accountability.
Likely supportive of the recognition and patient sympathy but cautious about expanding federal programs or subsidizing high‑cost therapies.
Prefers private‑sector innovation and oversight to prevent unintended costs.
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Still ahead
This is a nonbinding Senate resolution designating a day; it does not create binding law and thus cannot 'become law' by itself.
The bill has not accumulated any surfaced votes yet.
All support recognition, but differ on follow‑up funding and federal role
This is a nonbinding Senate resolution designating a day; it does not create binding law and thus cannot 'become law' by itself.
Relative to its intended legislative type, this bill functions as a straightforward commemorative resolution. It specifies the date to be designated and sets out concise recognition language; the factual preamble suppli…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.